Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment: Two Day Issues and Solutions Seminar (San Diego, CA, United States - October 3-4, 2019) - ResearchAndMarkets.com

DUBLIN--()--The "Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions" conference has been added to ResearchAndMarkets.com's offering.

The objective of this two day highly interactive seminar is to explore raw materials and their requirements - issues and solutions. It will also explore how water impacts the final product since water is the single largest raw material that is used within most processes. Another objective is to assure that your organization is maintaining itself within a cGMP compliance framework to include ICH Q7, Q9 and Q11. Case studies to include Warning Letters will be discussed to illustrate regulatory raw material issues.

Raw material requirements in a cGMP environment are often overlooked as a Company develops new products. Depending upon the product being developed, e.g., tablets and capsules vs. biotechnology products to include recombinant microorganisms and gene therapy products, as few as fifteen to twenty or as many as sixty raw materials need to be sourced before the process can be moved from initiation through completion.

This highly interactive two day seminar on raw material requirements in a cGMP environment will:

  • Consider FDA, Health Canada, ICH, USP and EP requirements-Compare and Contrast.
  • Review latest updates to include FDA, Health Canada, ICH, USP and EP requirements.
  • Examine a variety of the issues surrounding raw materials to include what materials should be tested and to what extent during Phase 1, 2, 3 and commercial production.
  • Cover testing requirements during each Phase (Phase appropriate), to include microbial and endotoxin, and what may be optional (regulatory risk) until the product moves to its next Phase.
  • Determine what options exist - even within a Phase 2 or Phase 3 testing framework.
  • Discuss compendial vs. non-compendial testing and how to respond when no method is available.
  • Discuss how a 90 percent vs. a 90.0 percent minimum purity analysis can delay initiation of testing.
  • Explore the number of lots required for testing before reduced testing might occur and why some companies don't accept this route.
  • Review the use of individual samples vs. composite samples for testing.
  • Explore ASQ testing to include how to choose attributes and sample size
  • Determine when the appropriateness of using ASQ vs. square root of N+1

Learning Objectives:

Upon completing this course on raw material requirements in a cGMP environment participants will:

  • Understand how various types of raw materials may impact the user.
  • Learn of the impact of raw materials to include any bacterial and endotoxin issues in the timely production of a product.
  • Determine the single most used raw material in large molecule production and what it means to the user.
  • Find the sources of analyses assistance for raw materials.
  • Appreciate the requirements for Phase 1 through commercial manufacturing - why safety is required as part of Phase 1
  • Initiation of additional testing - when?
  • Examination of regulatory risk to include ICH Q7, Q9 and Q11.
  • Why use compendial testing in lieu non-compendial testing.
  • Testing requirements - when is enough?
  • The impact of ASQ vs. square root of N+1 on sample size and attribute testing.

Who Should Attend:

  • Quality professionals
  • Regulatory professionals
  • Compliance professionals
  • Manufacturing engineers
  • Quality engineers
  • Quality auditors
  • Quality Control
  • Microbiology
  • Document control specialists
  • R & D
  • Project Managers

Agenda:

Day 1

  • 08.30 AM - 09.00 AM: Registration
  • 09.00 AM: Session Start
  • Consider FDA, Health Canada, ICH, USP and EP requirements - Compare and Contrast
  • The various raw materials and the user impact
  • Impact of raw materials in the timely production of a product
  • The impact of the single most used raw material in large molecule production and its impact upon the user
  • The regulatory requirements for Phase 1 through commercial manufacturing
  • The use of additional testing - does one only review the C of A

Day 2

  • The use of compendial testing in lieu of non-compendial testing - pros and cons
  • Regulatory risk (ICH Q9) with raw materials
  • Testing requirements - how to sample
  • Testing requirements - how to test
  • The impact of ASQ and square root of N+1 on sample size and attribute testing
  • Case Studies - Time to apply the previous two days
  • Warning Letter examples

For more information about this conference visit https://www.researchandmarkets.com/r/n2gb8p

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900